In our large cohort of 446 breast cancer patients undergoing neoadjuvant treatment, we confirmed the strong relationship between HER2-low-positive breast cancer and HR-positive status, thus strengthening the possible crucial role or ER signaling in shaping HER2-low-positive breast cancer biology5,17–21. Here, ERBB2 is linked to breast cancer.